HeimGRAL • NASDAQ
add
Grail Inc
38,36 $
Eftir lokun(0,16%)-0,060
38,30 $
Lokað: 6. jún., 19:54:45 GMT-4 · USD · NASDAQ · Lagalegir fyrirvarar
Við síðustu lokun
39,49 $
Dagbil
36,94 $ - 40,88 $
Árabil
12,33 $ - 63,99 $
Markaðsvirði
1,38 ma. USD
Meðalmagn
1,50 m.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | mar. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 31,84 m. | 19,15% |
Rekstrarkostnaður | 133,71 m. | -34,94% |
Nettótekjur | -106,21 m. | 51,48% |
Hagnaðarhlutfall | -333,61 | 59,28% |
Hagnaður á hvern hlut | -3,10 | — |
EBITDA | -114,36 m. | 38,98% |
Virkt skatthlutfall | 27,46% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | mar. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 674,58 m. | 237,76% |
Heildareignir | 2,85 ma. | -28,32% |
Heildarskuldir | 433,94 m. | 85,87% |
Eigið fé alls | 2,41 ma. | — |
Útistandandi hlutabréf | 35,97 m. | — |
Eiginfjárgengi | 0,58 | — |
Arðsemi eigna | -13,17% | — |
Ávöxtun eigin fjár | -15,21% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | mar. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | -106,21 m. | 51,48% |
Handbært fé frá rekstri | -95,01 m. | 54,16% |
Reiðufé frá fjárfestingum | 14,61 m. | 673,43% |
Reiðufé frá fjármögnun | — | — |
Breyting á handbæru fé | -80,34 m. | -178,66% |
Frjálst peningaflæði | -38,94 m. | 61,34% |
Um
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California. It was previously a subsidiary of Illumina started as a startup seeking to develop an early cancer screening test for people who do not have symptoms.
Grail was spun-out from Illumina on June 24, 2024.
Their liquid biopsy was launched in June 2021 and is called the Galleri test. Promoted as groundbreaking, the test performed poorly in testing and Grail has subsequently faced discontent and legal action from investors claiming they have been misled about the test's potential. Wikipedia
Stofnsett
2015
Höfuðstöðvar
Vefsvæði
Starfsfólk
1.000
